GMAB Stock Genmab A/S
STRONG BUY US · NasdaqGSStrong oncology franchise and pipeline visibility offer attractive forward value.
Future value: $45.04 (+0.79%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Steady pipeline execution and resilient momentum.
- ▸Above 50-day MA (+25.97%)
- ▸Above 200-day MA — long-term uptrend
- ▸Volume 2.28× average — accumulation
- ▸Near 52-week high (96.5% of range) — strength
Is GMAB a buy right now?
Trend: GMAB is trading above the 50-day average (+25.98%), RSI 31 — neutral momentum, with a 3-month return of +54.09%.
Valuation & quality: Genmab A/S trades on a trailing P/E of 34.9, forward P/E 29.5, PEG 5.44, price-to-book 4.48; fundamentals show net margin 19.1%, return on equity 14.0%, revenue growth 24.9% year on year.
Analyst consensus: 11 analysts have a mean 12-month price target of $48.27 (+8% vs the last close; range $33.50 – $60.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 5) — Strong oncology franchise and pipeline visibility offer attractive forward value.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -8.90% | -1.20% | -0.70% | +4.30% | +5.10% | +14.90% | +7.60% | +25.30% |
Fundamentals
Analyst price target
Technical signals
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Sector: Healthcare · Industry: Biotechnology · Denmark · 3,119 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.